OptimizeRx Corporation (OPRX) received a Buy rating from William Blair analyst Ryan Daniels today. The company’s shares closed yesterday at $12.04.
According to TipRanks.com, Daniels is ranked #368 out of 5110 analysts.
OptimizeRx Corporation has an analyst consensus of Moderate Buy.
See today’s analyst top recommended stocks >>
Based on OptimizeRx Corporation’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $244.9K. In comparison, last year the company had a GAAP net loss of $237.1K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.
